GeoVax Labs, Inc. is a clinical-stage biotechnology company headquartered in Atlanta, Georgia, that focuses on the development of immunotherapies and vaccines for serious infectious diseases. Leveraging a Modified Vaccinia Ankara (MVA) virus-like particle (VLP) platform, GeoVax engineers the expression of key pathogen antigens to stimulate durable cellular and humoral immune responses. The company was founded in 2001 to translate novel vaccine technologies from academic research into scalable biotechnology solutions.
GeoVax’s lead product candidate, GOVX-B11, is an HIV vaccine designed to elicit a robust T-cell response through sequential MVA-VLP prime-boost dosing. In addition to its HIV program, the company is advancing preclinical and early-stage candidates targeting filoviruses such as Ebola and Marburg, as well as mosquito-borne pathogens like Zika virus. Each candidate leverages the same MVA-based VLP approach to present antigens in a manner intended to mimic natural infection while maintaining a strong safety profile.
The company’s technology platform has been supported through collaborations and funding agreements with U.S. government agencies, including the National Institute of Allergy and Infectious Diseases (NIAID), and non-profit research organizations. GeoVax conducts its preclinical studies and clinical trials primarily in the United States, with an eye toward addressing global health challenges in regions hardest hit by emerging and re-emerging diseases.
Management is led by a team of industry veterans with backgrounds in vaccine research, development and regulatory affairs. GeoVax continues to leverage its academic origins and public-sector partnerships to advance its pipeline, aiming to bring next-generation vaccines to market for diseases with high unmet medical need.
AI Generated. May Contain Errors.
